Cargando…

Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series

Background. Lennox–Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy (DEE) in which drug resistance to antiepileptic drugs (AEDs) is common. Focal-onset seizures (FOS) are among the seizure types characterizing LGS. Cenobamate (CNB) is a new AED indicated for the treatment of FO...

Descripción completa

Detalles Bibliográficos
Autores principales: Falcicchio, Giovanni, Lattanzi, Simona, Negri, Francesco, de Tommaso, Marina, La Neve, Angela, Specchio, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821211/
https://www.ncbi.nlm.nih.gov/pubmed/36614931
http://dx.doi.org/10.3390/jcm12010129
_version_ 1784865643258970112
author Falcicchio, Giovanni
Lattanzi, Simona
Negri, Francesco
de Tommaso, Marina
La Neve, Angela
Specchio, Nicola
author_facet Falcicchio, Giovanni
Lattanzi, Simona
Negri, Francesco
de Tommaso, Marina
La Neve, Angela
Specchio, Nicola
author_sort Falcicchio, Giovanni
collection PubMed
description Background. Lennox–Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy (DEE) in which drug resistance to antiepileptic drugs (AEDs) is common. Focal-onset seizures (FOS) are among the seizure types characterizing LGS. Cenobamate (CNB) is a new AED indicated for the treatment of FOS and it has shown promising results in terms of seizure frequency reduction in both clinical trials and real-world experience. To date, the use of CNB in patients with DEEs is limited to Dravet syndrome. Methods: This was a retrospective study aimed to determine the 12-month effectiveness and tolerability of CNB in patients with LGS following real-world practice. Results: Four patients with LGS receiving CNB treatment were identified. At 12 months from starting CNB, the reduction in baseline seizure frequency ranged from 25 to 74%, with two patients achieving ≥50% seizure reduction. CNB was generally well tolerated and adjustments in doses of concomitant AEDs were required. Conclusions: CNB may represent a promising therapeutic option in patients with drug-resistant epilepsy associated with LGS. Further research is needed to confirm this preliminary evidence.
format Online
Article
Text
id pubmed-9821211
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98212112023-01-07 Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series Falcicchio, Giovanni Lattanzi, Simona Negri, Francesco de Tommaso, Marina La Neve, Angela Specchio, Nicola J Clin Med Communication Background. Lennox–Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy (DEE) in which drug resistance to antiepileptic drugs (AEDs) is common. Focal-onset seizures (FOS) are among the seizure types characterizing LGS. Cenobamate (CNB) is a new AED indicated for the treatment of FOS and it has shown promising results in terms of seizure frequency reduction in both clinical trials and real-world experience. To date, the use of CNB in patients with DEEs is limited to Dravet syndrome. Methods: This was a retrospective study aimed to determine the 12-month effectiveness and tolerability of CNB in patients with LGS following real-world practice. Results: Four patients with LGS receiving CNB treatment were identified. At 12 months from starting CNB, the reduction in baseline seizure frequency ranged from 25 to 74%, with two patients achieving ≥50% seizure reduction. CNB was generally well tolerated and adjustments in doses of concomitant AEDs were required. Conclusions: CNB may represent a promising therapeutic option in patients with drug-resistant epilepsy associated with LGS. Further research is needed to confirm this preliminary evidence. MDPI 2022-12-24 /pmc/articles/PMC9821211/ /pubmed/36614931 http://dx.doi.org/10.3390/jcm12010129 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Falcicchio, Giovanni
Lattanzi, Simona
Negri, Francesco
de Tommaso, Marina
La Neve, Angela
Specchio, Nicola
Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series
title Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series
title_full Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series
title_fullStr Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series
title_full_unstemmed Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series
title_short Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series
title_sort treatment with cenobamate in adult patients with lennox–gastaut syndrome: a case series
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821211/
https://www.ncbi.nlm.nih.gov/pubmed/36614931
http://dx.doi.org/10.3390/jcm12010129
work_keys_str_mv AT falcicchiogiovanni treatmentwithcenobamateinadultpatientswithlennoxgastautsyndromeacaseseries
AT lattanzisimona treatmentwithcenobamateinadultpatientswithlennoxgastautsyndromeacaseseries
AT negrifrancesco treatmentwithcenobamateinadultpatientswithlennoxgastautsyndromeacaseseries
AT detommasomarina treatmentwithcenobamateinadultpatientswithlennoxgastautsyndromeacaseseries
AT laneveangela treatmentwithcenobamateinadultpatientswithlennoxgastautsyndromeacaseseries
AT specchionicola treatmentwithcenobamateinadultpatientswithlennoxgastautsyndromeacaseseries